Early day motion tabled by primary sponsor Paul Monaghan (Scottish National Party), on Thursday, 1 December 2016, in the House of Commons. It is signed by 14 members in total.

---

DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG)

That this House recognises that diffuse intrinsic pontine glioma (DIPG) is the second most common type of primary, high grade brain tumour in children and affects 20 to 30 children in the UK each year; further recognises that DIPG symptoms include abnormal alignment of the eyes, weakness of facial muscles, difficulty speaking and walking, headaches and nausea; notes there is currently no effective treatment as DIPG tumours are not amenable to surgery due to their location in the brainstem; further notes that there is a severe lack of funding for the research of DIPG with a fraction of cancer research funding going towards such brain tumours; welcomes the research and work undertaken by organisations such as the Brain Tumour Charity that continues to investigate the genetic foundation of DIPG to develop new targeted drugs; and calls on the Government to increase funding committed to researching DIPG to further improve and enhance recognition and treatment of this unfortunate and deeply concerning disease.

---

Secondary information

Type

Early day motion

Reference

758 

Session

2016-17

Other sponsors

Mark Durkan

Jim Shannon

Martyn Day

Natalie McGarry

John McNally

Subjects

Diseases

Link

View this Early day motion on www.parliament.uk